Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Kenya

Kenya

The revenue generated in the Other Vaccines market in Kenya is projected to reach US$25.18m in 2025.
It is expected to demonstrate an annual growth rate (CAGR 2025-2029) of 10.11%, leading to a market volume of US$37.01m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$27,370.00m in 2025.
Kenya is experiencing an increasing demand for other vaccines, driven by the government's efforts to expand immunization programs and improve public health.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Other Vaccines in Kenya has been steadily increasing in recent years.

Customer preferences: Kenyan customers have become increasingly aware of the importance of vaccination in preventing diseases. They are also becoming more proactive in seeking out vaccines for themselves and their families. This is partly due to the efforts of the Kenyan government and healthcare providers to raise awareness about the benefits of vaccination.

Trends in the market: The Other Vaccines market in Kenya has been growing steadily due to increasing demand for vaccines. The market is dominated by multinational pharmaceutical companies, which have a strong presence in the country. These companies have been investing in research and development to create new vaccines that are more effective and affordable.

Local special circumstances: Kenya has a high burden of infectious diseases such as malaria, tuberculosis, and HIV/AIDS. The government has been working to improve access to healthcare services, including vaccination, to address these health challenges. In addition, Kenya has a large population of children under the age of five, who are particularly vulnerable to infectious diseases. This has led to a focus on childhood vaccination programs in the country.

Underlying macroeconomic factors: Kenya has a growing economy, which has led to an increase in disposable income and healthcare spending. This has enabled more people to afford vaccines and other healthcare services. In addition, the government has been investing in the healthcare sector, which has helped to improve access to healthcare services, including vaccination. However, there are still challenges to be addressed, such as improving vaccine distribution and reaching remote areas of the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.